Updated information on COVID-19 and Flu: Restricted visitation is now in effect
Sub Category
Nasopharynx Carcinoma
Study Name
NRG-HN001: Randomized Phase II AND Phase III Studies of Individualized Treatment for Nasopharyngeal Carcinoma Based on Biomarker Epstein Barr Virus (EBV) Deoxyribonucleic Acid (DNA)
Principal Investigator
Gordan Srkalovic
Study Information
Contact for Questions
Clinical Trials Office – 517.364.9400

Site view: at a glance